

 [Print this Page for Your Records](#)
[Close Window](#)**Program#/Poster#:** 58/B273**Abstract Title:** **Presbyopic Profile With The Mel 80. Preliminary Experience****Presentation Start/End Time:** Sunday, Apr 30, 2006, 8:30 AM -10:15 AM**Location:** Hall B/C**Reviewing Code:** 266 presbyopia correction: cures & basic understanding - VI

Author Block: *J.L. Guell¹, F.Manero, IV¹, M.Sisquella¹, J.C. Ondategui², J.Pujol³, M.Arjona³.*
¹Cornea-Refractive, IMO, Barcelona, Spain; ²Centro de desarrollo de sensores, instrumentacion y sistemas (cd6), UNIVERSIDAD POLITECNICA DE CATALUÑA, Terrassa, barcelona, Spain; ³Centro de desarrollo de sensores, instrumentacion y sistemas (cd6), UNIVERSIDAD POLITECNICA DE CATALUÑA, TERRASSA, Barcelona, Spain.

Keywords: 638 presbyopia, 616 optical properties

Purpose: We will present our preliminary experience using a different approach on excimer ablation, based in the manipulation of the final spherical aberration value (polynomium Z(40))

Methods: We evaluated the results of the treatment in 17 eyes of 13 patients, with mean age of 45 years. Asphericity changes were measured with a Hartmann-Shack aberrometer (WASCA, Zeiss Meditec) and amplitude of accommodation were measured objectively with the double-pass based instrument (OQAS (Optical Quality Analysis System, Visiometrics).

A standart myopic or hyperopic treatment was combined with aberrometric correction of a fourth-order aberrometric correction of a fourth-order aberration to obtain the desired increase in spherical aberration

Results: Subgroup analysis showed that near vision with distance correction improved in the myopic eyes, was stable in the hyperopic eyes and had a marked increase in the pseudophakic eyes, both myopic and hyperopic.

Measurements with the WASCA aberrometer showed that, as we expected, spherical aberration increased in all groups, especially in the hyperopic group.. Clinically non-significant but important data came from the OQAS analysis. Amplitude of accommodation increased between 1.25D and 2.25D and was again particularly notable in the pseudophakic eyes.

Conclusions: The treatment proved to be safe, with no loss of high or low contrast visual acuity in any of the patients. The efficacy on near vision was remarkable in most cases, without any loss of distance vision quantity and quality

Commercial Relationship: **J.L. Guell**, ZEISS, MEDITEC, C; VISIOMETRICS, P; **F. Manero**, None; **M. Sisquella**, None; **J.C. Ondategui**, None; **J. Pujol**, VISIOMETRICS, P; **M. Arjona**, None.

Support: McyT DPI2002-00118&FIT-020400-49

©2006, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to www.iovs.org to access the version of record. For permission to reproduce any abstract, contact the ARVO Office at arvo@arvo.org.



-- Indicates International Multi-Country Collaboration

OASIS - Online Abstract Submission and Invitation System™ ©1996-2006, Coe-Truman Technologies, Inc.